Here are the Form 4 insider transactions from Atrium Therapeutics, Inc. (RNA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNA filings page.
Atrium Therapeutics, Inc. (RNA) reported that Chief Scientific Officer Younis Husam had 11,216 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units. Following this tax-withholding disposition, he directly holds 41,441 shares of Atrium common stock.
Atrium Therapeutics, Inc. (RNA) reported that Chief Medical Officer Steven George Hughes had 21,459 shares51,638 shares
Atrium Therapeutics, Inc. (RNA) director Michael W. Flanagan reported a Form 4 reflecting the withholding of 22,812 shares of Common Stock on September 18, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. After this tax-withholding disposition, he holds 31,974 shares of Common Stock directly.
Atrium Therapeutics, Inc. (RNA) reported that director Sarah Boyce had 126,418 shares of Common Stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. After this withholding transaction, she directly holds 138,668 shares of Atrium Therapeutics common stock. No Rule 10b5-1 trading plan is reported for this Form 4.
Atrium Therapeutics, Inc. (RNA) reported that Chief Corporate Affairs Officer Stephanie Kenney had 2,375 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from vesting of restricted stock units. After this tax-withholding disposition, she directly holds 33,085 shares of common stock. No Rule 10b5-1 plan is reported.
Atrium Therapeutics, Inc. (RNA) reported that Chief Executive Officer, President and director Kathleen P. Gallagher had 11,632 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations related to vesting restricted stock units. These shares were not sold in the market, and she continued to hold 119,729 shares of common stock directly afterward.
Atrium Therapeutics, Inc. (RNA) reported that Chief Financial Officer Brendan R. Winslow had 6,742 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. The shares were treated as a disposition and his directly held stake is now 36,859 shares. No Rule 10b5-1 trading plan is reported.
Atrium Therapeutics, Inc. (RNA) reported that Chief Strategy Officer Rocio Martin Hoyos had 8,320 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations upon the vesting of restricted stock units. The shares were treated as a disposition at a reference price of $8.95 per share, and Hoyos now holds 38,340 common shares directly. No Rule 10b5-1 trading plan is reported for this transaction.
Atrium Therapeutics, Inc. granted equity awards to executive Stephanie Kenney on April 20, 2026. She received 30,000 shares of common stock as restricted stock units, bringing her direct common stock holdings to 35,460 shares after the award.
Kenney was also granted stock options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over multiple years starting March 20, 2027, subject to her continued service with the company.
Atrium Therapeutics’ Chief Medical Officer Steven George Hughes reported new equity compensation consisting of restricted stock units and stock options. He received 30,000 RSUs, each representing one future share of common stock, bringing his directly held common shares to 73,097 after the award.
The RSUs vest over four years, with 25% vesting on March 20, 2027 and the rest in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036.
These options vest with 25% becoming exercisable on March 20, 2027 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter, also subject to continued service.
Atrium Therapeutics, Inc. reported that its Chief Financial Officer, Brendan R. Winslow, received equity compensation consisting of restricted stock units and stock options. He was granted 30,000 shares of Common Stock as an award, bringing his direct holdings to 43,601 shares after the transaction.
He was also granted 60,000 stock options to buy Common Stock at an exercise price of $14.30 per share, expiring on April 20, 2036. According to the award terms, 25% of the RSUs vest on March 20, 2027, with the remainder vesting in three yearly installments. For the options, 25% of the underlying shares vest on March 20, 2027, with the remaining shares vesting in 36 substantially equal monthly installments. These are compensation-related grants, not open-market purchases.
Atrium Therapeutics, Inc. director and officer Kathleen P. Gallagher reported receiving equity awards as part of her compensation. She was granted 102,500 shares of common stock in the form of restricted stock units, with each unit representing one future share of common stock, subject to vesting.
Gallagher was also granted a stock option for 205,000 shares of common stock at an exercise price of $14.30 per share. Twenty-five percent of both the RSUs and the option vest on March 20, 2027, with the remaining portions vesting over subsequent years, contingent on her continued service. After these grants, she directly owns 131,361 shares of common stock and holds the full 205,000-share stock option.
Atrium Therapeutics, Inc. reported that Chief Strategy Officer Rocio Martin Hoyos received equity-based compensation. She was granted 30,000 shares of common stock in the form of restricted stock units and now holds 46,660 common shares directly after this award.
She was also granted a stock option for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over several years starting March 20, 2027, contingent on continued service with the company.
Atrium Therapeutics, Inc. Chief Scientific Officer Husam Younis reported equity compensation awards. He received 30,000 shares of common stock as restricted stock units, which vest 25% on March 20, 2027 and then in three yearly installments, contingent on continued service. He was also granted options for 60,000 shares of common stock at an exercise price of $14.30 per share, vesting 25% on March 20, 2027 and the balance in 36 equal monthly installments through April 20, 2036. Following the stock award, his direct common stock holdings total 52,657 shares.